CCSD code 0299B: Sarcosine level test billing guide

Key Takeaways

CCSD code 0299B identifies a Sarcosine level test in the Biochemistry category of the CCSD Schedule. It’s the code a lab or provider puts on an invoice to bill a UK private insurer for this specific blood test.

It’s a pathology code, not a surgical or clinical procedure code. Sarcosine (N-methylglycine) is an amino acid measured to investigate a suspected inherited metabolic condition or as part of a wider amino acid profile, not to perform an operation.

Sarcosine has also been studied as a possible prostate cancer biomarker, but the evidence is mixed and it isn’t an accepted standalone screening test. Insurers can query a claim more readily when the referral reads like screening rather than a documented clinical indication.

Bupa, AXA Health, Aviva, Vitality Health, and WPA all recognise CCSD codes for pathology claims, submitted mainly through Healthcode. Practice management software like Pabau helps practices attach the correct code, ordering clinician detail, and specimen date before a claim goes out.

CCSD code 0299B is the code UK private medical insurers use to bill a Sarcosine level test — a blood test that measures sarcosine, an amino acid involved in the body’s one-carbon metabolism pathway. It sits in the Biochemistry category of the CCSD Schedule, alongside the other single-analyte and metabolic blood tests insurers process every day.

If an invoice or remittance shows 0299B, that’s the charge for the Sarcosine result specifically. It has nothing to do with an operation, a consultation, or any clinician’s procedure fee.

This guide covers what 0299B actually pays for, why a Sarcosine level is requested and what the evidence behind it shows, how the test moves from a clinician’s request through to a paid claim, and a before-you-submit checklist for keeping a Sarcosine claim out of the query pile.

If you’re new to running a private practice in the UK, pathology billing is one of the areas where the rules genuinely differ from surgical or consultation billing, so it’s worth getting right from the first invoice.

What CCSD code 0299B covers

0299B identifies a Sarcosine level test on the CCSD Schedule — the number a lab or provider puts on an invoice line to tell an insurer exactly what was checked.

Sarcosine, also known as N-methylglycine, is a naturally occurring amino acid that sits in the metabolic pathway linking choline, glycine, and folate-dependent one-carbon metabolism. The body makes it from glycine and breaks it back down to glycine via the enzyme sarcosine dehydrogenase.

Clinicians request a Sarcosine level most often to investigate a suspected inherited metabolic condition called sarcosinemia, where reduced sarcosine dehydrogenase activity lets sarcosine build up in the blood — a finding that’s generally considered clinically benign on its own.

It’s followed up because it can also flag an underlying folate deficiency or a vitamin B12 deficiency such as pernicious anaemia, coded D51.0.

Sarcosine has a second, more contested clinical story. A widely cited 2009 study proposed it as a biomarker for aggressive prostate cancer, and the finding drew significant attention at the time.

Since then, larger studies — including a prospective analysis from a major US cancer screening trial — found the result didn’t hold up consistently, and at least one large case-control study concluded serum sarcosine added nothing beyond standard risk factors already captured under R97.20.

Sarcosine is not a validated or guideline-recommended prostate cancer screening test, and a clinician requesting it for that reason is working from an active area of research rather than an established diagnostic pathway.

Most labs measure Sarcosine as part of a broader quantitative plasma amino acid profile run on tandem mass spectrometry, rather than as an isolated single-analyte test, though a repeat draw is sometimes requested if an initial newborn or metabolic screen flags an abnormal result.

As a pathology test, 0299B sits in the CCSD Schedule’s Biochemistry category, not among the surgical or procedure codes.

A note on the code itself: CCSD codes pair a numeric family with a trailing letter, and public sources disagree on what any individual suffix is supposed to denote.

The Schedule’s full narrative sits behind a registered login, so this guide sticks to what can be confirmed: 0299B identifies a Sarcosine level test in the Biochemistry category, without asserting what the letter on its own is supposed to mean.

Check the live CCSD Schedule or your Healthcode portal for related diagnostic codes, such as 0081H or 0049C, that might apply to a different specimen type or a repeat test.

What CCSD is, and why UK private billing runs on it

Zooming out from the code itself: CCSD stands for Clinical Coding and Schedule Development. It’s both the name of the schedule and the group that governs it. Representatives from Bupa, AXA Health, Aviva, and Vitality Health, alongside several private hospital groups, oversee what codes exist and what they cover, while Grant Thornton UK LLP administers the schedule day to day.

For clinicians moving from the NHS into private practice, this is one of the first practical differences to learn. There’s no equivalent governing body on the NHS side, because NHS activity isn’t billed code-by-code to a payer the way private care is.

The Schedule splits into a Procedural Schedule and a Diagnostic Schedule, covering everything from surgical procedures to consultations to lab-based diagnostic tests like 0299B. Crucially, the CCSD Group doesn’t set fees.

Bupa, AXA Health, Aviva, and every other insurer that recognises the Schedule sets its own reimbursement rate for each code, and a code existing on the Schedule is no guarantee that a specific insurer will pay for it under a specific policy.

Treat any fee figure you see quoted online as indicative at best, and confirm the number with the insurer directly.

How CCSD differs from NHS coding

The NHS doesn’t use CCSD at all. NHS procedure activity is classified using OPCS-4, officially the OPCS Classification of Interventions and Procedures, maintained by NHS England, which absorbed NHS Digital’s classification functions when the two organisations merged in February 2023. Diagnoses use ICD-10 alongside it.

Private billing runs on CCSD, so a clinician working across both settings is, in effect, working in two coding languages: One for what the NHS records for activity and outcomes data, and a different one entirely for what gets invoiced to a private insurer.

How a Sarcosine test actually gets billed to insurers

Here’s the sequence, from the clinician’s request to the insurer’s remittance:

1. The clinician requests the test. A GP, metabolic specialist, or urologist orders a Sarcosine level — usually to follow up an abnormal newborn or metabolic screen, to check for a folate- or B12-related metabolic disturbance, or, less commonly and more contentiously, as part of a specialist prostate-health or biomarker panel.
2. A blood sample is taken. A single venous blood draw is all that’s needed. Because sarcosine shares a close structural resemblance with alanine isomers, the analysing lab needs a method — typically LC-MS/MS or a validated amino acid analyser — that can separate sarcosine cleanly from those isomers, rather than a routine chemistry assay.
3. The sample is sent to the lab. Sarcosine analysis typically runs through a specialist biochemistry, metabolic, or inherited metabolic disease laboratory rather than the practice’s in-house point-of-care testing.
4. The lab analyses the sample and issues a pathology report. The report states the Sarcosine level against the lab’s reference range, usually alongside the wider amino acid profile it was run within.
5. The lab or provider codes and bills the claim through Healthcode. 0299B goes out referencing the ordering clinician’s provider number and the specimen date.
6. The insurer adjudicates the claim, and the practice reconciles the payment against the pathology report.

That’s the mechanical flow, and it’s a short one. The friction with a test like this rarely comes from the clinical side — it comes from the analysis itself.

A Sarcosine result generated on a method that can’t fully resolve it from its structural isomers is a result an insurer’s own medical team, or a second-opinion lab, can challenge on technical grounds, not just a documentation one.

The second friction point sits earlier, at the referral itself. Because the evidence for Sarcosine as a prostate cancer biomarker remains unsettled, and because amino acid panels also show up in wellness and longevity-style health screens, insurers are increasingly alert to claims that aren’t tied to a documented clinical indication.

A claim for 0299B linked to a confirmed metabolic finding, a genuine sarcosinemia work-up, or a specific symptom moves through in the same way as any other routine pathology test.

A claim where the referral letter reads like a general biomarker or wellness panel, with no diagnosis or abnormal prior result driving it, is far more likely to be queried or declined as not medically necessary, regardless of whether the code itself is correct.

Take a practical case: A private GP orders a Sarcosine level after a child’s expanded metabolic screen flags a mild elevation, to help distinguish primary sarcosinemia from a secondary cause such as folate deficiency. The lab bills 0299B, referencing the GP’s provider number and the specimen date.

Because the referral letter states the abnormal screening result and the specific clinical question, the claim clears without a query. Had the same test been ordered as a stand-alone item on a general biomarker panel with no abnormal prior result or stated clinical reason, it’s a claim insurers are far more likely to hold pending clarification.

Documentation requirements for pathology claims

Insurers can ask for the paperwork behind a 0299B claim months after the result was reported, and a thin file is hard to defend at audit even when the invoice itself was correct. Three things are worth having on record before you bill, not after a query letter shows up.

• The clinical indication. Why the Sarcosine level was requested — an abnormal metabolic screen, a suspected folate or B12 deficiency, or a documented clinical reason for a biomarker test — needs to trace back to the patient’s notes, even if it’s only a line.
• The ordering clinician’s detail and the specimen collection date. The GP or consultant who requested the test, their provider number, and the date the sample was taken should match what’s on the claim and the lab report. A mismatch here is one of the most common reasons a pathology claim bounces.
• The lab report itself, including the analytical method used. Keep the pathology report on file against the patient record, not just the invoice line, and note the method the lab used given sarcosine’s known isomer-interference issue.

Before you submit a 0299B claim

Turn that documentation habit into a broader pre-submit check, and most of the queries a Sarcosine claim attracts never get the chance to happen. Run through this before the claim goes out, not after a rejection lands:

• Correct code for what actually ran. Confirm 0299B is the right code for the Sarcosine level requested, rather than a related code covering a different specimen type or a repeat test.
• Clinical indication documented, and distinguishable from wellness or biomarker screening. A line in the notes that ties the test to a diagnosis, an abnormal prior result, or a monitoring plan, not just a general health panel.
• Ordering clinician’s provider number current. Checked against what’s on file, not what was there at the last recognition renewal.
• Pre-authorisation confirmed where the insurer asks for it. Don’t assume a single blood test is automatically folded into a wider authorisation.
• Specimen collection date and analytical method logged. Matching what’s on the lab report, so a query about the sample doesn’t turn into a query about the whole claim.
• Documentation retained under the practice’s normal retention policy. No separate Sarcosine-specific rule to invent here.

Which insurers recognise CCSD pathology codes

Bupa, AXA Health, Aviva, Vitality Health, and WPA all recognise CCSD codes, including pathology codes like 0299B and 0537G, and process the majority of these claims through Healthcode’s clearing service. Healix recognises and processes CCSD-coded claims too, though it works as a healthcare trust and claims administrator rather than a traditional insurer.

Reimbursement rates and pre-authorisation requirements still vary by payer and by policy, so confirm both before you bill rather than assuming last quarter’s answer still holds. For Bupa specifically, the Bupa CCSD codes guide covers how to use its code search portal to confirm a code before an appointment.

Common billing mistakes with pathology claims like 0299B

Billing problems on a Sarcosine claim almost always fall into a small number of repeating categories, and most of them are about data matching rather than clinical judgement.

• Wrong or mismatched code. Billing 0299B for a Sarcosine level run on a different specimen type, or against a repeat test that carries a different code, is one of the most frequent code-level errors on pathology claims like this.
• Missing or assumed pre-authorisation. Assuming a Sarcosine test is automatically folded into a wider authorisation, without confirming it with the insurer, is a common reason claims stall, particularly where the referral looks more like screening than a diagnostic work-up.
• Specimen or lab documentation errors. A missing specimen collection date, an unlogged analytical method, or a pathology report that isn’t filed against the patient record all show up at audit even when the original invoice was correct.
• Unit or quantity errors. Billing more than one unit for a single blood draw, or duplicating the line when a repeat draw was actually a retest rather than a second charge, both attract queries.
• Outdated code or fee reference. Billing software that hasn’t been updated against the current CCSD Schedule can carry a superseded description or fee reference, which triggers a query even when the clinical work was correct.
• Thin documentation trail. Skipping the clinical indication or ordering clinician detail covered above still shows up regularly in insurer audits, even when the invoice itself was accurate.

How practice management software like Pabau supports CCSD pathology billing

Practices that manage CCSD billing manually, across spreadsheets and separate insurer portals, carry compounding administrative risk. Every manual step is a chance for a mismatched provider number, a missing specimen date, or a claim raised under the wrong pathology code.

Practice management software like Pabau helps by keeping the clinical record and the billing record in one system, rather than splitting them across a separate spreadsheet for codes.

Pabau also integrates natively with Healthcode, so a Sarcosine test claim, the CCSD code, the ordering clinician’s provider number, and the specimen date, can be submitted, validated, and tracked without re-keying it into a separate portal.

Practices can hold CCSD codes like 0299B inside a saved investigation template, so a Sarcosine test gets coded the same way every time a claim goes out, instead of re-typed from memory on each invoice.

Keep pathology claims moving

Pabau supports UK private practices with a CCSD code library, native Healthcode claim submission, and structured documentation that ties the clinical indication, provider number, and specimen detail to every pathology claim. See how it works for your practice.

Book a demo

Conclusion

CCSD code 0299B is straightforward once the premise is right. It’s how UK private insurers bill for a Sarcosine level test, a blood test that sits within the Biochemistry category of the CCSD Schedule, not a procedure with an operative note behind it.

Most of the claim problems that come up with it aren’t clinical at all. They typically come down to:

• A mismatched provider number.
• A missing clinical indication that would separate it from wellness screening.
• A specimen that wasn’t analysed with a method that can reliably resolve sarcosine from its structural isomers.

The bigger job is building a pathology billing process that still holds up as the practice takes on more of these tests: One where the ordering clinician’s detail and the specimen date don’t depend on one person remembering the rule, and where a stalled claim gets caught before it turns into a three-month-old unpaid invoice.

Pabau’s claims management software helps UK private practices keep pathology claims like this one moving, from code validation through to Healthcode submission. To see how it handles a Sarcosine test claim end to end, book a demo.

Continue your research

Want to see how a different CCSD pathology code plays out? CCSD code 0080S covers what it means, how the claim moves through Healthcode, and why there’s no fixed fee.

Billing a virus DNA test for a private patient? CCSD code 0309O covers the Varicella zoster virus DNA test and how it’s billed to UK insurers.

Need the code for an antibody test claim? CCSD code 0527C covers the Flavivirus IgG antibody test and its billing route through Healthcode.

Thinking about opening your own practice? Nurse practitioner private practice walks through the steps of setting up independently.

Ordering a wider blood panel alongside a Sarcosine level? Basic metabolic panel template gives you a starting point for recording the wider result set.

Frequently asked questions